Thrombocytopenia Caused by Abciximab or Tirofiban and Its Association with Clinical Outcome in Patients Undergoing Coronary Stenting

Piera Angelica Merlini, Marco Rossi, Alberto Menozzi, Silvia Buratti, Danielle M. Brennan, David J. Moliterno, Eric J. Topol, Diego Ardissino

Research output: Contribution to journalArticlepeer-review

Abstract

Background-Thrombocytopenia is a possible complication of treatment with glycoprotein (GP) IIb/IIIa antagonists during percutaneous coronary interventions, but it is not clear whether different GP IIb/IIIa inhibitors carry a different risk of thrombocytopenia, and its relation to clinical outcome is unknown. Methods and Results-We analyzed data from the Do Tirofiban and Reopro Give Similar Efficacy Outcomes (TARGET) study, which compared the safety and efficacy of abciximab and tirofiban in patients undergoing coronary stenting. Platelets were measured at baseline and 6 and 24 hours after the beginning of treatment. Thrombocytopenia (nadir platelet count 9 cells/L) developed in 2.4% of patients treated with abciximab and 0.5% of those treated with tirofiban (P

Original languageEnglish
Pages (from-to)2203-2206
Number of pages4
JournalCirculation
Volume109
Issue number18
DOIs
Publication statusPublished - May 11 2004

Keywords

  • Anticoagulants
  • Platelets
  • Stents
  • Thrombosis

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Fingerprint

Dive into the research topics of 'Thrombocytopenia Caused by Abciximab or Tirofiban and Its Association with Clinical Outcome in Patients Undergoing Coronary Stenting'. Together they form a unique fingerprint.

Cite this